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Abstract
Learning disabilities are relatively common conditions in pediatric population. The inci-
dence of learning disability ranges from 1% to 17%, reflecting that learning disability may 
be not a single clinical entity but a wide distribution of cognitive traits in the population. 
As reported by the American Association on Intellectual and Developmental Disabilities 
(AAIDD), among the prenatal learning disability causes, chromosomal disorders, genetic 
syndromes, and inborn errors of metabolism must be taken into account. In this chapter, 
we will focus the attention on RASopathies, genetic disorders characterized by germ-
line mutations in the RAS-MAPK pathway whose role is crucial in the regulation of the 
cell cycle, differentiation, growth, and cell senescence. This group of disorders includes 
Noonan syndrome, neurofibromatosis type 1, Costello syndrome (CS), Legius syndrome, 
Noonan syndrome with multiple lentigines, and cardiofaciocutaneous syndrome. 
Mutations in RAS-MAPK pathways lead to impairments in synaptic plasticity, necessary 
for normal brain function, especially for learning and memory. Variation across the RAS/
MAPK pathway syndromes suggests that different gene mutations affecting this path-
way can have markedly different developmental effects.
Keywords: learning disabilities, RASopathy, long-term potentiation, RAS, ERK, MAPK, 
neurofibromatosis, Noonan syndrome, Costello syndrome, Legius syndrome, LEOPARD, 
CFC
1. Introduction
Learning disabilities are relatively common pediatric conditions, and there is no universal 
consensus establishing what a learning disability represents [1, 2]. The American Pediatrics 
Association subcategorizes specific learning disorder as reading, written expression, or 
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mathematics skills that are substantially lower than expected for the individual’s age, mea-
sured intelligence, and age-appropriate education level or when achievement falls below a 
set standard definition [3]. The International Classification of Disease (ICD) identifies learn-
ing disability as a condition of arrested or incomplete development in cognitive functioning 
or in adaptive behavior in the developmental period [4]. It can be evaluated with the general 
intelligence functioning and supplemented by scales.
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) is available 
from 2013. The DSM-V now indicates a unique new category or diagnosis of “specific learning 
disorder” for issues previously differentiated as: dyslexia, dyscalculia, dysgraphia, and dys-
orthography. The change was made because there had been no support for a continued dis-
tinction among the terms. The single definition joined the “specifiers,” and for each of them, 
the deficit capacities are mentioned with reference to the reading, calculation, and the written 
language. The DSM-V state classifies the disorder in mild, moderate, and severe. In addition, 
the risk factors are confirmed as the disturbance of language, familiarity, co-morbidity [5].
During last decades, many studies have been conducted to understand the basis of these 
neurodevelopmental disorders, leading to the identification of some altered specific neural 
networks although the mechanisms are not fully understood [6–9].
In this context, the American Association on Intellectual and Developmental Disabilities 
(AAIDD) identifies prenatal, perinatal, and postnatal causes. Among the prenatal causes, 
chromosomal disorders, Syndrome disorders (RASopathies), and inborn errors of metabolism 
can be taken into account; perinatal and postnatal causes often encompass infectious and trau-
matic etiologies. Several cognitive deficits may be caused by a single-gene mutation and can 
be classified into discrete clinical conditions with specific diagnoses [10, 11]. Notwithstanding 
distinct clinical entities could rise from the interaction between genes and environment.
A better understanding of pathophysiological mechanisms that lead to learning disability 
could provide new insights in knowledge and therapy of intellectual and learning disabilities.
2. RASopathies
RASopathies are a group of genetic developmental syndromes with phenotypic overlapping 
features caused by germline mutation in genes that encode components or regulators of RAS/
mitogen-activated protein kinase (MAPK) pathway. Approximately, these syndromes affect 1 
in 1000 live births, being one of the most common group syndromes. This group includes neu-
rofibromatosis type I (OMIM #162200), Legius syndrome (OMIM #611431), Noonan syndrome 
(OMIM #163950), Noonan syndrome with multiple lentigines (formerly called LEOPARD 
syndrome, OMIM #151100), Costello syndrome (CS) (OMIM #218040), cardiofaciocutaneous 
(CFC) syndrome (OMIM #115150), Noonan-like syndrome, hereditary gingival fibromatosis, 
and capillary malformation-arteriovenous malformation [9–14]. Several functionally related 
genes, such as PTPN11 (OMIM *176876, mapped in 12q24.13 region), SOS1 (OMIM *182530, 
2q22.1), KRAS (OMIM *190070, 12p12.1), BRAF (OMIM *164757, 7q34), RAF1 (OMIM *164760, 
3p25.2), MAP2K1 (OMIM *176872, 15q22.31), MAP2K2 (OMIM *601263, 19p13.3), RIT1 (OMIM 
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*609591, 1q22), NRAS (OMIM *164790, 1p13.2), RRAS (OMIM *165090, 19q13.33), SOS2 
(OMIM *601247, 14q21.3), SHOC2 (OMIM *602775, 10q25.2), CBL (OMIM *165360, 11q23.3), 
NF1 (OMIM *613113, 17q11.2), HRAS (OMIM *190020, 11p15.5), and SPRED1 (OMIM *609291, 
15q14), have been associated to the pathogenesis of these disorders [12–32].
Although clinical presentation can be similar, every disorder has its peculiar features (as 
shown in Table 1). They share common central nervous system dysfunction leading to learn-
ing disability-intellectual disability, cardiovascular abnormalities, dismorphic features, short 
stature, skeletal malformation, coetaneous lesions (tumors, spots, vascular malformation), 
and increasing risk of benign or malignant tumors (e.g. Figure 1).
Syndrome Gene Phenotypic features
Neurofibromatosis type I (NF1) NF1 Multiple café-au-lait spots, skin-fold freckling, 
neurofibromas, short stature, macrocephaly, 
Lisch nodules, vasculopathy, aneurysm, stenosis, 
arteriovenous malformation, optic pathway glioma
Noonan syndrome PTPN11, SOS1, RAF1, 
RIT1, KRAS, NRAS, 
BRAF, RRAS
Relative macrocephaly, distinctive facial features, 
short stature, mild developmental/cognitive 
impairment, webbed neck, cryptorchidism, Pectus 
excavatum, myeloproliferative disorder, cardiovascular 
abnormalities (pulmonary stenosis, atrial septal defect 
and others)
Noonan syndrome with multiple 
lentigines (LEOPARD)
PTPN11, RAF1, BRAF Multiple lentigines, electrocardiographic conduction 
abnormalities, ocular hypertelorism, pulmonary 
stenosis, abnormal genitalia, retardation of growth and 
sensorineural deafness, hypertrophic cardiomyopathy
Legius syndrome SPRED1 Multiple café-au-lait spots, skin-fold freckling, 
macrocephaly, learning disability, lipomas, NS-like 
face/characteristics
Costello syndrome HRAS Failure to thrive, distinctive facial features, feeding 
difficulties, short stature, curly hair, palmar keratosis, 
increased risk of malignant tumors (~10–15%), 
congenital heart defects, hypertrophic cardiomyopathy
Cardiofaciocutaneous (CFC) 
syndrome
BRAF, MAP2K1, 
MAP2K2, KRAS
Failure to thrive, distinctive facial features, skin 
abnormalities including nevi, lentigines and 
palmarplantar keratosis, curly hair, severe intellectual 
disability, seizure, pulmonary valvular stenosis, 
hypertrophic cardiomyopathy, septal defects, cardiac 
valve anomalies
Noonan-like syndrome SHOC2, CBL Macrocephaly, short stature with growth hormone 
deficiency, fine, sparse and easily pluckable hair, mild 
neurocognitive impairment, hyperpigmented skin 
lesions, microcephaly, cardiovascular abnormalities
Hereditary gingival fibromatosis SOS1 Gingival fibromatosis
Capillary malformation-
arteriovenous malformation
RASA1 Capillary malformation, arteriovenous malformation
Table 1. Classification of RASopathies with gene correlation and phenotypic features.
Learning Disability in RASopathies
http://dx.doi.org/10.5772/intechopen.69571
29
Such complex phenotypes derive from mutation in the Ras/mitogen-activated protein kinase 
(MAPK) pathway which plays an essential role in regulation of cell cycle, differentiation, 
growth and cell senescence [12, 15, 16]. Focusing on these signaling alterations, there was a 
hyperactivation of extracellular-regulated kinase 1/2 (ERK1/2; member of the MAPK super-
family) in all of these disorders. This kind of signal could be induced by mutations in positive 
regulators, producing gain-of-function alleles or in negative regulators (neurofibromin 1), loss-
of-function alleles, of the RAS/ERK signaling pathway. Oyshi et al. ruled out this mechanism 
only in Noonan syndrome with multiple lentigines (LEOPARD syndrome), where mutation in 
the gene PTPN11 (Y729C and T468M) encoding for protein tyrosine phosphatase SHP-2 results 
in a loss-of-function and a decrease in the level activity of ERK1/2 [33].
Figure 1. Typical signs of RASopathies: a) Pterigium colli (the clinical signs are wanted); b) Pectus escavatum; c) Cubitius 
valgus; d) Axillary freckling: a sign which initially show; e) From strains to nodules and fibroids.
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Variation across the Ras/MAPK pathway syndromes suggests that different mutant alleles of 
gene can have markedly various developmental effects, flowing in several syndromes. At the 
same time, the same allele mutant can produce different phenotypes because of the interaction 
with the environment, the epigenetic variation, and the action of others gene.
Recent advances in genetic analysis technologies, including whole-exome sequencing, have 
identified potential new genes for RASopathies [12].
2.1. The Ras/mitogen-activated protein kinase (MAPK) pathway
The Ras/mitogen-activated protein kinase (MAPK) pathway has a crucial role in regulating cell 
cycle and development, transducting signals from membrane receptors activated by growth 
factors to the cytoplasm and nucleus. This cascade is tightly regulated [16, 23, 34, 35]. For a 
better understanding, see Figure 2.
Figure 2. The Ras/MAPK signal transduction pathway of protein kinases is critically involved in cellular proliferation, 
differentiation, motility, apoptosis, and senescence. Mutation of genes encoding components or regulators of the Ras/
MAPK pathway (indicated by dashed lines) cause medical genetics syndromes named RASopathies. These disorders 
include neurofibromatosis type 1 (NF1). Noonan syndrome (NS), Noonan syndrome with multiple lentigines 
(NSML), capillary malformation-arteriovenous malformation syndrome (CM-AVM), Costello syndrome (CS), cardio-
facio-cutaneous syndrome (CFC), Leopard syndrome (LeoS), Legius syndrome (Legs), and ALPS (Autoimmune 
lymphoproliferative syndrome). RTK is the Receptor Tyrosine Kinase.
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RAS genes, including HRAS, NRAS and KRAS, encode for small guanosine nucleotide-bound 
GTPases which are positively matched with different kind of receptors, inducing a transfor-
mation in an active GTP-bound form and an inactive Guanosine Diphosphate (GDP) bound 
form. Activation of RAS through receptor tyrosine kinases (RTKs) occurs thanks to recruit-
ment of the adaptor protein growth factor receptor bound protein 2 (GRB2) and son of seven-
less (SOS) which increase the level of active GTP-bound Ras [36–38].
After RAS activation, the signaling cascade is turned on with the activation of RAF (ARAF, 
BRAF, and/or CRAF), which activates, phosphorylating the MAPK kinases, MEK1 and/or 
MEK2 and, in turn, ERK1 and ERK2. ERK1 and ERK2 are the effectors of the cascade and con-
trol a large number of nuclear and cytosolic molecules owning as target cell cycle progression, 
cellular differentiation, and cellular growth.
Among the negative regulators of this cascade, neurofibromin 1 (NF1) is a GTPase-activating 
protein that is a negative regulator of RAS (RAS-GAP) and the Sprouty-related protein with 
an EVH-1 domain SPRED1 [16, 35–39].
2.2. Basis of learning disability in RASopathies
Since 1997 the central role of RAS-ERK signaling has been identified in long-term potentiation 
(LTP), in long-term depression (LTD), in synaptic plasticity, in memory formation and learning 
during the development, including spatial learning and fear conditioning, therefore not only 
in cell growth, proliferation, migration, and survival [40–45].
So far, many studies have neglected the psychological and psychiatric profile of RASopathies, 
but new contributions of literature are proving that it is just the tip of the iceberg [46].
In central nervous system (CNS), synaptic plasticity is a prerequisite for learning and memory. 
First studies in animal models of RASopathies have provided interesting findings on the bio-
logical basis of these disabilities, examining the RAS/ERK functions that unfortunately are not 
completely understood.
The long-term potentiation (LTP) and the long-term depression (LTD) are prerequisite for syn-
aptic plasticity in key areas as hippocampus, amygdala, insular cortex, and prefrontal cortex. 
N-methyl-d-aspartate (NMDA) receptors and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptors (AMPA) are closely related to these mechanisms. After high-frequency release of 
glutamate and activation of AMPA receptors, NMDA magnesium block is removed resulting in 
a more sustained excitatory. NMDA receptors lead to intracellular calcium influx and AMPA 
phosphorylation of AMPA receptors and movement to the cell surface bringing to an increas-
ing answer to glutamate release. Furthermore, calcium influx can promote the transcription of 
crucial gene for the LTP trough cAMP-dependent signaling cascade involving PKA, mitogen-
activated protein kinases (MAPK), and the transcription factor cAMP-responsive element bind-
ing protein (CREB). On the other hand, low-frequency stimulation induces LTD through a weak 
calcium influx inducing dephosphorylation and endocytosis of AMPA receptors [47].
Increased activity of RAS-ERK pathway in keys areas of the brain (as hippocampus, para- 
hippocampus, amygdale, prefrontal) can lead, on the one hand, to an increased activity of 
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GABAergic interneurons, and on the other hand, to an impaired signaling in glutamatergic syn-
apses and consequently to dysruption of synaptic plasticity through LTP or LTD. In GABAergic 
synapses, RAS-MAPK pathway regulates the phosphorylation of synapsin I in presynaptic 
neurons, where it is critically involved in maintaining the vesicle reserve pool and regulating 
the rate of neurotransmitter vesicle release. Neurofibromin 1 negatively regulates Ras/MAPK 
signaling pre-synaptically in hippocampal-GABAergic neuron; as a matter of fact, mutations in 
the gene of NF1 induce an enhanced GABA release. As for glutamatergic synapses, RAS-ERK 
pathway is activated by tyrosine kinase receptors (TRK) or calcium influx activated through 
N-methyl-d-aspartate (NMDA) receptors or voltage-gated calcium channels, playing a key role 
in the transcription of many crucial genes for long-term potentiation. Modulation of glutamater-
gic synapses is necessary to modify AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor) receptor expression on cells surface, enhancing the basal excitatory synaptic trans-
mission, blocking further potentiation of synaptic strength. Consistently, an hyper-activation of 
RAS-ERK signaling, for example, could be also due to a SHP2 mutation, enhancing the basal 
excitatory synaptic transmission, facilitating the synaptic trafficking of AMPA receptors to syn-
apses with the subsequent events before described (for more information see: [45, 47–53]).
Recently, the importance of RAS-MAPK pathway has been also revealed in differentiation of 
neuron progenitor cells. Disruption of this cascade can result in an imbalance between neuro-
genesis and glycogenesis [35].
Several neurophysiological studies have been conducted in patients with RASopathies by 
using transcranial magnetic stimulation (TMS), a noninvasive and safe way to investigate 
neuronal plasticity. Several experimental paradigms applying the so-called paired associa-
tive stimulation (PAS) have demonstrated that patients with neurofibromatosis type I and 
Noonan syndrome have reduced LTP-like synaptic plasticity depending on an increased 
intracortical inhibition. On the contrary, TMS studies in Costello syndrome (CS) patients have 
shown enhanced LTP-like synaptic plasticity related to reduced inhibition [51, 54–56].
In summary, there are strong evidences that the deregulation of activity of RAS-MAPK sig-
naling can lead to LTP impairment and altered neuronal plasticity resulting in learning and 
memory impairment.
3. Focus on learning disability in every RASopathy
3.1. Neurofibromatosis type 1
Neurofibromatosis type I was the first RASopathies identified, it is a genetic disorder caused 
by mutations in the neurofibromin 1 gene (NF1) at locus 17q11.2, resulting in loss-of-function 
of its protein product. Neurofibromatosis type I has an autosomal dominant inheritance, as 
homozygous mutations appear to be lethal and has an incidence of approximately 1 in 2600–
3000 individuals [39, 57, 58].
This syndrome is characterized by the presence of café-au-lait maculae (spots), (axillary and 
inguinal) intertriginous freckling, neurofibromas and plexiform neurofibromas, iris Lisch 
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nodules, osseous dysplasia, optic pathway glioma, and/or a first-degree relative with NF1. 
Up to 65% of NF1 patients show cognitive impairments which frequently involve executive 
and higher order cognitive domain [14, 16, 39, 48, 49, 57–59].
Neurofibromin acts as a RAS-GAP (GTPase activating protein) and negatively regulates Ras 
signaling, also working as an activator of adenylate cyclase. Its mutation brings to a hyperacti-
vation of the RAS-MAPK signaling cascade and to an increased GABA-mediated inhibition of 
interneurons, significantly reducing long-term potentiation in hippocampus and amygdala. 
The role of NF1 is crucial in maintaining the balance between RAS- and cAMP-dependent 
signaling [38, 47, 48, 56–58].
Reading/vocabulary, visuospatial functions, motor coordination, planning, and organi-
zational skills are often impaired. High co-morbidity with attention deficit hyperactivity 
disorder (ADHD) is explained by frequent impairment of working memory, cognitive 
flexibility, and inhibitory control. Patients with NF1 show both nonverbal (poor perfor-
mance in tests of visuospatial functioning and spatial learning, impairments in the abil-
ity to perceive social cues, poor organizational skills, and increased impulsiveness) and 
verbal-type learning disability (expressive and receptive language, vocabulary, visual nam-
ing, and phonologic awareness). A single mutation can give rise to a complex spectrum of 
learning disabilities [39, 60, 61].
Emerging insights from the pathophysiology of this syndrome have provided new potential 
targets for learning disability therapy. A randomized, double-blind, placebo-controlled study 
evaluated the influence of lovastatin on impaired synaptic plasticity in patients with NF1. 
By decreasing the ERK basal activation, lovastatin reduces RAS-pathway hyperactivity with 
a significant improvement in verbal and nonverbal memory, visual attention, and efficiency 
[15, 54, 56, 58, 61].
3.2. Noonan syndrome
Noonan syndrome is an autosomal dominant genetic disorder with a prevalence approxi-
mately of 1 every 1000–2500 live births, caused by activating germline mutations in the 
PTPN111 gene in 50% of affected individuals, but other cases have shown to be caused by 
gain-of-function mutations in KRAS (fewer than 50%), SOS1 (approximately in 13%), RAF1, 
and RIT1 (in 5%). Other genes have been reported in literature which is associated with 
Noonan syndrome, for example, NRAS, BRAF, and MAP2K1 [14, 55, 62–66].
Mutation in PTPN11 induces alteration of function in the protein SHP2 (nonreceptor tyrosine 
phosphatase) which loses its ability to switch from the active to the inactive protein conforma-
tion, causing an increased signaling in Ras/MAPK cascade. Its role is crucial in determining 
neuronal cell fate and regulating the generation of oligodendrocytes. Hyperactivity of Ras/
MAPK cascade increases delivery of AMPA receptors to the synapses, enhancing the basal 
excitatory synaptic transmission. Mutations in SOS1 induce loss-of-function in auto-inhibition 
and gain-of-function in the protein product RAS-GEF protein which acts as a stimulator of the 
conversion of RAS from the inactive to the active form. Mutations of KRAS and BRAF also 
determine RAS/MAPK up-regulation [35, 62–66].
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This syndrome is typically characterized by facial anomalies, short stature, family history, 
chest carinatum/excavatum, congenital heart defects (pulmonary valve stenosis, septal defects 
and hypertrophic cardiomyopathy, atrial and ventricular septal defects, branch pulmonary 
artery stenosis, and tetralogy of Fallot), lymphatic dysplasia, cryptorchidism, varied coagula-
tion defects, and learning disabilities [64, 65].
A wide variability of cognitive complaints has been recognized ranging from absent or mild 
learning problems to severe intellectual disabilities and depends on type of mutation. Patients 
with SOS1 mutations performed significantly higher on both verbal and nonverbal cognitive 
tests than individuals with PTPN11 and other kinds of mutations. Several studies have dem-
onstrated that these patients have a greater risk to have impaired performance in verbal free 
recall task than in visual and spatial recognition memory tasks. Furthermore, Pierpont et al. 
showed that children with Noonan syndrome have different performance on verbal memory 
tasks, on visual memory, or working memory. Better performances have been obtained in 
immediate verbal memory than in delayed free recall tasks; a more pronounced hippocampal 
and prefrontal cortex dysfunction may probably reflect RAS-MAPK aberration in memory 
formation and consolidation [62, 63, 65–67].
Likewise, NF1 promising studies on the therapeutic effect of lovastatin in mice with mutation 
in PTPN11 are currently underway thanks to its action in decreasing basal Erk activation and 
seem to represent a therapeutic strategy for learning deficits Noonan syndrome [68].
3.3. Legius syndrome (NF1 like)
Legius syndrome is an autosomal dominant genetic disorder caused by germline mutations in 
the SPRED1 which induce loss-of-function in the product protein. It is typically characterized 
by multiple café au lait macules without neurofibromas or other tumors, intertriginous freck-
ling, lipomas, macrocephaly, and learning disabilities/ADHD/developmental delays [57, 69].
SPRED1 is a negative regulator of the Ras/MAPK pathway, being a substrate of SHP2, and 
its mutation leads to a hyperactivation of this cascade, and in animal models, it also has been 
seen that mice have some deficits in hippocampus-dependent spatial learning and in several 
phases of visual discrimination learning [35, 70].
3.4. LEOPARD syndrome
LEOPARD syndrome (Noonan syndrome with multiple lentigines) is an autosomal domi-
nant genetic disorder, caused by mutation in PTPN11 (p.Y279C and p.T468P) and RAF1. 
Phenotypically, they have the same features of Noonan syndrome patient but with multiple 
lentigines, electrocardiogram abnormalities, pulmonary valve stenosis, abnormal genitalia, 
growth retardation, and ocular hypertelorism [14, 16, 17, 35, 71].
Several studies conducted in vitro have demonstrated that mutation in PTPN11 leads to 
a reduced catalytic activity in SHP2 causing a loss-of-function, despite studies conducted 
in animal models have demonstrated that this residual activity is sufficient to generate a 
gain-of-function like phenotype in the cascade that leads to a hyperactivation of Ras/MAPK 
pathway [14, 16, 35, 71].
Learning Disability in RASopathies
http://dx.doi.org/10.5772/intechopen.69571
35
In this syndrome, learning disability are reported in the 30% of cases [54] and are more 
evident in verbal recall memory performance but relative sparing of visual and spatial 
recognition memory [16, 66, 71].
3.5. Costello syndrome
Costello syndrome is one of the rare syndromes of the group of RASopathies. It is caused by 
heterozygous activating germline mutations in HRAS. Typically, it is a missense mutation that 
induced the reduction of the intrinsic GTPase activity of RAS, which remains in the active form 
facilitating the synaptic trafficking of AMPA receptors. Besides, it has been seen that its action 
occurs in the spine dendritic structures too, which presents an increased density [14, 16, 35, 72].
This syndrome is phenotypically characterized by failure to thrive; short stature; develop-
mental delay or intellectual disability; coarse facial features, curly, or sparse fine hair; loose, 
soft skin with deep palmar and plantar creases; papillomatosis of the face and perianal region; 
diffuse hypotonia and joint laxity; cardiac involvement (cardiac hypertrophy, valvar pul-
monic stenosis, arrhythmia); relative or absolute macrocephaly Chiari I malformation with 
associated anomalies including hydrocephalus or syringomyelia. Moreover, they present an 
increased risk, approximately 15%, to malignant tumors [14, 16, 72].
Particularly, in these patients, it has been observed that verbal learning and memory are 
impaired but are better than the nonverbal cognitive abilities, while the visual associative mem-
ory is performed in the mildly disabled, but the related data are not completely clear [35, 73].
3.6. CFC syndrome
Cardiofaciocutaneous (CFC) syndrome is a very rare RASopathy. It is caused by heterozy-
gous activating mutations in BRAF (~75%), MAP2K1, and MAP2K2 (~25%), KRAS (<2%) that 
cause a deregulation of the RAS-MAPKinase cascade in a positive way. It is inherited in an 
autosomal dominant manner [14, 16, 74, 75].
CFC is characterized by craniofacial dysmorphology, congenital heart disease (pulmonic 
stenosis and other valve dysplasias, septal defects, hypertrophic cardiomyopathy, and rhythm 
disturbances), dermatologic abnormalities (xerosis, hyperkeratosis, ichthyosis, keratosis pilaris, 
ulerythema ophryogenes, eczema, pigmented moles, hemangiomas, and palmoplantar 
hyperkeratosis), growth retardation, and intellectual and learning disability [14, 16, 74, 75].
Assessing the learning ability, CFC patients present significant delay in adaptive skills, 
impaired spatial learning, and hippocampal long-term potentiation. It has been evidenced 
disability in verbal skills, especially the communication abilities were more impaired than the 
comprehension and in spatial learning [35, 75].
Mutations in MAP2K1, which are frequently associated with neurological complications 
and intellectual disability, can be associated with a milder clinical and neurocognitive pro-
file more typical of individuals with Noonan syndrome. Variability of expression may arise 
from a complex interplay between RAS/MAPK pathway genotype, epigenetics, medical and 
obstetric factors, and environmental influences [76].
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4. Conclusion
Children with RASopathies show commonly learning disabilities, such as impaired reading/
vocabulary, visuospatial functions, motor coordination, planning, and organizational skills. 
Variability of expression may arise from a complex interplay between RAS/MAPK pathway 
genotype, epigenetics, medical and obstetric factors, and environmental influences. Emerging 
insights from the pathophysiology of these different genetic syndromes may facilitate the 
development of mechanism-based individualized treatment and may provide new potential 
targets for learning disability therapy in patients with RASopathies.
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